|

SANGAMO THERAPEUTICS INC (SGMO)

US8006771062 - Common Stock

0.4501  -0.03 (-7.2%)

After market: 0.4501 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

SANGAMO THERAPEUTICS INC

NASDAQ:SGMO (12/11/2023, 3:31:02 PM)

After market: 0.4501 0 (0%)

0.4501

-0.03 (-7.2%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap79.72M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

SGMO Daily chart

Company Profile

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Brisbane California, California and currently employs 478 full-time employees. The company went IPO on 2000-04-06. The firm focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; TX200, its wholly owned Chimeric Antigen Receptor (CAR), engineered regulatory T cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A., and BIVV003, its zinc finger nuclease, or ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD).

Company Info

SANGAMO THERAPEUTICS INC

7000 Marina Blvd

Brisbane California CALIFORNIA 94005

P: 15109706000.0

CEO: Alexander D. Macrae

Employees: 478

Website: https://www.sangamo.com/

SGMO News

News Image13 days ago - ChartmillWhat's going on in today's after hours session

Curious about the stocks that are showing activity after the closing bell on Tuesday?

News Image19 days ago - BloombergA Biotech Slump Is Emptying Labs and Threatening Research on New Drugs

Sangamo Therapeutics Inc.’s cost cuts didn’t hurt just the roughly 162 US workers who lost their jobs this month. It’s also a blow to Jerry Walter, who’s lost five family members and suffered kidney, lung, hearing and heart damage from a rare disease.

News Imagea month ago - Seeking AlphaRBC Capital downgrades Sangamo as biotech moves to save cash (SGMO)

RBC Capital downgrades Sangamo Therapeutics (SGMO) due to workforce cuts and program pauses, lowering price target to $2 from $6. Read more here.

News Imagea month ago - Sangamo Therapeutics, Inc.Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
News Image2 months ago - Sangamo Therapeutics, Inc.Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
News Image2 months ago - Sangamo Therapeutics, Inc.Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

SGMO Twits

Here you can normally see the latest stock twits on SGMO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example